Development in Left Ventricular Mass After Early and Late Conversion From Calcineurin Inhibitors to Everolimus in Heart Transplant Recipients—Results From Two Randomized Controlled Trials
Open Access
- 9 October 2026
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 40 (10) , e70705
Abstract
Left ventricular hypertrophy in heart transplant recipients has been attributed to the use of calcineurin inhibitors. We assessed left ventricular mass across treatment arms in 83 heart transplant recipients in the Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE), and in 75 maintenance recipients in the Nordic Certican Trial in Heart and Lung Transplantation (NOCTET). In SCHEDULE, we randomized participants to treatment with calcineurin inhibitors or replacement with everolimus within 7–11 weeks after transplant. In NOCTET, participants were randomized to treatment with calcineurin inhibitors or a combination of low dose calcineurin inhibitors and everolimus. We followed patients with echocardiography for 3 years in the SCHEDULE trial and for 5 years in NOCTET. In SCHEDULE, left ventricular mass diminished with time, particularly across the first year of follow‐up (everolimus arm: −10 ± 18 g/m 2 , cyclosporine arm: −9 ± 13 g/m 2 ). However, there was no between‐group difference in this development ( p = 0.91). In NOCTET, there was no significant change in LVM over time and no between‐group difference in the change ( p = 0.27). In conclusion, t he replacement of calcineurin inhibitors with everolimus or a reduction in the calcineurin inhibitor dose did not mitigate left ventricular hypertrophy after heart transplantation. Trial Registration: SCHEDULE—ClinicalTrials.gov Identifier: NCT01266148; NOCTET—ClinicalTrials.gov Identifier: NCT00377962Keywords
Funding Information
- Novartis
This publication has 30 references indexed in Scilit:
- Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trialThe Journal of Heart and Lung Transplantation, 2024
- Everolimus for the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy After Heart Transplantation (RADTAC Study)JACC: Heart Failure, 2021
- Imaging in Heart Transplant PatientsJACC: Cardiovascular Imaging, 2018
- Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2016
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2015
- The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report—2013; Focus Theme: AgeThe Journal of Heart and Lung Transplantation, 2013
- Severe Left Ventricular Hypertrophy 1 Year After Transplant Predicts Mortality in Cardiac Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2007
- Echocardiography in the Cardiac Transplant RecipientHeart Failure Clinics, 2007
- American Society of Echocardiography recommendations for use of echocardiography in clinical trialsJournal of the American Society of Echocardiography, 2004
- Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findingsThe American Journal of Cardiology, 1986